Randy F. Sweis, MD; Pablo Gajate, MD; Rafael Morales-Barrera, MD; et al.
This nonrandomized clinical trial evaluates the safety, pharmacokinetics, and preliminary efficacy of rogaratinib in combination with the programmed cell death 1 ligand 1 inhibitor atezolizumab in cisplatin-ineligible patients with FGFR messenger RNA–positive, locally advanced/metastatic urothelial cancer.